Serena Mazzucchelli

Proteomic and biochemical analyses unveil tight interaction of ataxin-3 with tubulin.

HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches.

Single-domain protein A-engineered magnetic nanoparticles: toward a universal strategy to site-specific labeling of antibodies for targeted detection of tumor cells.

Investigating the structural biofunctionality of antibodies conjugated to magnetic nanoparticles.

Highly efficient production of anti-HER2 scFv antibody variant for targeting breast cancer cells.

HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice.

Multiple presentation of Scfv800E6 on silica nanospheres enhances targeting efficiency toward HER-2 receptor in breast cancer cells.

Site-specific conjugation of ScFvs antibodies to nanoparticles by bioorthogonal strain-promoted alkyne-nitrone cycloaddition.

Protein oriented ligation on nanoparticles exploiting O6-alkylguanine-DNA transferase (SNAP) genetically encoded fusion.

Protein-assisted one-pot synthesis and biofunctionalization of spherical gold nanoparticles for selective targeting of cancer cells.

Orientation-controlled conjugation of haloalkane dehalogenase fused homing peptides to multifunctional nanoparticles for the specific recognition of cancer cells.

Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands.

Delivering colloidal nanoparticles to mammalian cells: a nano-bio interface perspective.

Interactions of ataxin-3 with its molecular partners in the protein machinery that sorts protein aggregates to the aggresome.

Antiproliferative effect of ASC-J9 delivered by PLGA nanoparticles against estrogen-dependent breast cancer cells.

Development of U11-functionalized gold nanoparticles for selective targeting of urokinase plasminogen activator receptor-positive breast cancer cells.

Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in Cancer Cells.

Peptide-nanoparticle ligation mediated by cutinase fusion for the development of cancer cell-targeted nanoconjugates.

Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice.

The potential of protein-based nanocages for imaging and drug delivery.

Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer.

Oral delivery of insulin via polyethylene imine-based nanoparticles for colonic release allows glycemic control in diabetic rats.

Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies.

Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer.

Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy.

Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines.

Dependence of nanoparticle-cell recognition efficiency on the surface orientation of scFv targeting ligands.

Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model.

Indocyanine Green Nanoparticles: Are They Compelling for Cancer Treatment?

Development and validation of a simple and versatile method for the quantification of everolimus loaded in H-ferritin nanocages using UHPLC-MS/MS.

Combined Method to Remove Endotoxins from Protein Nanocages for Drug Delivery Applications: The Case of Human Ferritin.

Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax.

Tumor Accumulation and Off-Target Biodistribution of an Indocyanine-Green Fluorescent Nanotracer: An Ex Vivo Study on an Orthotopic Murine Model of Breast Cancer.